| EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non–small cell lung cancer: a retrospective analysis JF Gainor, AT Shaw, LV Sequist, X Fu, CG Azzoli, Z Piotrowska, ... Clinical cancer research 22 (18), 4585-4593, 2016 | 1205 | 2016 |
| Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation AN Hata, RM Breyer Pharmacology & therapeutics 103 (2), 147-166, 2004 | 1113 | 2004 |
| Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition AN Hata, MJ Niederst, HL Archibald, M Gomez-Caraballo, FM Siddiqui, ... Nature medicine 22 (3), 262-269, 2016 | 1004 | 2016 |
| The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics AN Hata, JA Engelman, AC Faber Cancer discovery 5 (5), 475-487, 2015 | 676 | 2015 |
| A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors M Slyper, CBM Porter, O Ashenberg, J Waldman, E Drokhlyansky, ... Nature medicine 26 (5), 792-802, 2020 | 563 | 2020 |
| Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor Z Piotrowska, MJ Niederst, CA Karlovich, HA Wakelee, JW Neal, ... Cancer discovery 5 (7), 713-722, 2015 | 515 | 2015 |
| The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution O Rozenblatt-Rosen, A Regev, P Oberdoerffer, T Nawy, A Hupalowska, ... Cell 181 (2), 236-249, 2020 | 458 | 2020 |
| Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for … Z Piotrowska, H Isozaki, JK Lennerz, JF Gainor, IT Lennes, VW Zhu, ... Cancer discovery 8 (12), 1529-1539, 2018 | 425 | 2018 |
| Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models RB Corcoran, KA Cheng, AN Hata, AC Faber, H Ebi, EM Coffee, ... Cancer cell 23 (1), 121-128, 2013 | 423 | 2013 |
| Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK … N Tanaka, JJ Lin, C Li, MB Ryan, J Zhang, LA Kiedrowski, AG Michel, ... Cancer discovery 11 (8), 1913-1922, 2021 | 392 | 2021 |
| Cycling cancer persister cells arise from lineages with distinct programs Y Oren, M Tsabar, MS Cuoco, L Amir-Zilberstein, HF Cabanos, JC Hütter, ... Nature 596 (7873), 576-582, 2021 | 345 | 2021 |
| Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer JJ Lin, VW Zhu, S Yoda, BY Yeap, AB Schrock, I Dagogo-Jack, NA Jessop, ... Journal of Clinical Oncology 36 (12), 1199-1206, 2018 | 335 | 2018 |
| Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer JF Gainor, D Tseng, S Yoda, I Dagogo-Jack, L Friboulet, JJ Lin, ... JCO precision oncology 1, 1-13, 2017 | 302 | 2017 |
| Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer S Yoda, JJ Lin, MS Lawrence, BJ Burke, L Friboulet, A Langenbucher, ... Cancer discovery 8 (6), 714-729, 2018 | 298 | 2018 |
| KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition S Misale, JP Fatherree, E Cortez, C Li, S Bilton, D Timonina, DT Myers, ... Clinical Cancer Research 25 (2), 796-807, 2019 | 239 | 2019 |
| Combination olaparib and temozolomide in relapsed small-cell lung cancer AF Farago, BY Yeap, M Stanzione, YP Hung, RS Heist, JP Marcoux, ... Cancer discovery 9 (10), 1372-1387, 2019 | 214 | 2019 |
| Genomic and functional fidelity of small cell lung cancer patient-derived xenografts BJ Drapkin, J George, CL Christensen, M Mino-Kenudson, R Dries, ... Cancer discovery 8 (5), 600-615, 2018 | 209 | 2018 |
| Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer S Raoof, IJ Mulford, H Frisco-Cabanos, V Nangia, D Timonina, E Labrot, ... Oncogene 38 (37), 6399-6413, 2019 | 199 | 2019 |
| Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer JJ Lin, SV Liu, CE McCoach, VW Zhu, AC Tan, S Yoda, J Peterson, A Do, ... Annals of Oncology 31 (12), 1725-1733, 2020 | 197 | 2020 |
| SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors L Dardaei, HQ Wang, M Singh, P Fordjour, KX Shaw, S Yoda, G Kerr, ... Nature medicine 24 (4), 512-517, 2018 | 196 | 2018 |
Justin GainorDirector, Center for Thoracic Cancers Program, Massachusetts General HospitalCorreu electrònic verificat a partners.org
